- Home
- TNYA vs AGEN Comparison
TNYA vs AGEN Comparison
Compare TNYA & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNYA
- AGEN
- Stock Information
- Founded
- TNYA 2016
- AGEN 1994
- Country
- TNYA United States
- AGEN United States
- Employees
- TNYA N/A
- AGEN N/A
- Industry
- TNYA Medicinal Chemicals and Botanical Products
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TNYA Health Care
- AGEN Health Care
- Exchange
- TNYA Nasdaq
- AGEN Nasdaq
- Market Cap
- TNYA N/A
- AGEN 38.1M
- IPO Year
- TNYA 2021
- AGEN 2000
- Fundamental
- Price
- TNYA $0.54
- AGEN $1.60
- Analyst Decision
- TNYA Strong Buy
- AGEN Buy
- Analyst Count
- TNYA 6
- AGEN 4
- Target Price
- TNYA $8.60
- AGEN $8.00
- AVG Volume (30 Days)
- TNYA 4.9M
- AGEN 503.7K
- Earning Date
- TNYA 03-10-2025
- AGEN 05-06-2025
- Dividend Yield
- TNYA N/A
- AGEN N/A
- EPS Growth
- TNYA N/A
- AGEN N/A
- EPS
- TNYA N/A
- AGEN N/A
- Revenue
- TNYA N/A
- AGEN $103,463,000.00
- Revenue This Year
- TNYA N/A
- AGEN $4.03
- Revenue Next Year
- TNYA N/A
- AGEN $5.57
- P/E Ratio
- TNYA N/A
- AGEN N/A
- Revenue Growth
- TNYA N/A
- AGEN N/A
- 52 Week Low
- TNYA $0.39
- AGEN $1.44
- 52 Week High
- TNYA $5.10
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- TNYA 35.78
- AGEN 28.09
- Support Level
- TNYA $0.62
- AGEN $1.44
- Resistance Level
- TNYA $0.69
- AGEN $1.77
- Average True Range (ATR)
- TNYA 0.07
- AGEN 0.14
- MACD
- TNYA 0.01
- AGEN 0.03
- Stochastic Oscillator
- TNYA 12.91
- AGEN 32.00
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).